LT3265448T - Riluzolo provaistai ir jų naudojimas - Google Patents
Riluzolo provaistai ir jų naudojimasInfo
- Publication number
- LT3265448T LT3265448T LTEPPCT/US2016/019787T LT16019787T LT3265448T LT 3265448 T LT3265448 T LT 3265448T LT 16019787 T LT16019787 T LT 16019787T LT 3265448 T LT3265448 T LT 3265448T
- Authority
- LT
- Lithuania
- Prior art keywords
- riluzole prodrugs
- riluzole
- prodrugs
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229960004181 riluzole Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127684P | 2015-03-03 | 2015-03-03 | |
PCT/US2016/019787 WO2016140879A1 (en) | 2015-03-03 | 2016-02-26 | Riluzole prodrugs and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3265448T true LT3265448T (lt) | 2022-04-11 |
Family
ID=56848452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2016/019787T LT3265448T (lt) | 2015-03-03 | 2016-02-26 | Riluzolo provaistai ir jų naudojimas |
Country Status (24)
Country | Link |
---|---|
US (9) | US10639298B2 (lt) |
EP (2) | EP3265448B1 (lt) |
JP (2) | JP6700293B2 (lt) |
KR (2) | KR20230147746A (lt) |
CN (1) | CN107567438B (lt) |
AU (3) | AU2016226463B2 (lt) |
BR (1) | BR112017018832B1 (lt) |
CA (1) | CA2978158C (lt) |
DK (1) | DK3265448T3 (lt) |
EA (1) | EA034759B1 (lt) |
ES (1) | ES2905318T3 (lt) |
HK (1) | HK1248706A1 (lt) |
HR (1) | HRP20220208T1 (lt) |
HU (1) | HUE058204T2 (lt) |
IL (2) | IL253989B (lt) |
LT (1) | LT3265448T (lt) |
MX (1) | MX2017011196A (lt) |
PH (1) | PH12017501576A1 (lt) |
PL (1) | PL3265448T3 (lt) |
PT (1) | PT3265448T (lt) |
RS (1) | RS62915B1 (lt) |
SG (2) | SG11201706831RA (lt) |
SI (1) | SI3265448T1 (lt) |
WO (2) | WO2016140879A1 (lt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
CN107249567B (zh) * | 2014-11-21 | 2021-08-03 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
US20210228549A1 (en) * | 2015-03-03 | 2021-07-29 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
US11911369B2 (en) | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
PL3265448T3 (pl) * | 2015-03-03 | 2022-04-25 | Biohaven Therapeutics Ltd. | Proleki riluzolu i ich zastosowanie |
JP2017061430A (ja) * | 2015-09-25 | 2017-03-30 | 芳男 ▲浜▼田 | 新規なプロドラッグ |
DK3458053T3 (da) | 2016-05-20 | 2022-02-21 | Biohaven Therapeutics Ltd | Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling |
WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US20210212999A1 (en) * | 2017-01-18 | 2021-07-15 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
US20180207138A1 (en) | 2017-01-23 | 2018-07-26 | Cadent Therapeutics, Inc. | Methods for the treatment of tremors by positive modulation of sk channels |
JP7083836B2 (ja) * | 2017-02-28 | 2022-06-13 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | アゼチジン誘導体 |
CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
US20210023061A1 (en) * | 2017-11-12 | 2021-01-28 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole prodrugs to treat ataxias |
JP2021530543A (ja) * | 2018-07-22 | 2021-11-11 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | アルツハイマー病を処置するためのリルゾールプロドラッグの使用 |
BR112021002692A2 (pt) * | 2018-08-16 | 2021-05-11 | Biohaven Therapeutics Ltd. | uso de comprimidos desintegrantes orais de riluzol para o tratamento de doenças |
GB201818651D0 (en) * | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
JP2022552834A (ja) * | 2019-10-10 | 2022-12-20 | バイオヘイブン・セラピューティクス・リミテッド | ミエロペルオキシダーゼ阻害剤のプロドラッグ |
EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics Llc | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS |
CA3187323A1 (en) * | 2020-06-24 | 2021-12-30 | Biohaven Therapeutics Ltd. | Compositions and methods for treating obsessive-compulsive disorder |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
EP4294384A1 (en) * | 2021-02-22 | 2023-12-27 | Yale University | Targeted bifunctional degraders |
KR20240025777A (ko) | 2022-08-19 | 2024-02-27 | 부산대학교 산학협력단 | 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물 |
WO2023165465A1 (zh) * | 2022-03-01 | 2023-09-07 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
WO2024006678A1 (en) * | 2022-06-26 | 2024-01-04 | Biohaven Therapeutics Ltd. | Methods of treating glioblastoma with prodrugs of riluzole |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999023083A1 (fr) * | 1997-11-05 | 1999-05-14 | Mitsubishi Chemical Corporation | Nouveaux derives alkylamino |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
US20050130974A1 (en) * | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
AR050258A1 (es) * | 2004-07-21 | 2006-10-11 | Mitsui Chemicals Inc | Derivado de diamina, proceso de la preparacion de este, y fungicida que contiene el derivado de diamina como ingrediente activo |
EP3753561A1 (en) | 2005-04-05 | 2020-12-23 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
FR2885129B1 (fr) * | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
US10357497B2 (en) | 2012-06-23 | 2019-07-23 | Biohaven Pharmaceutical Holding Company Limited | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis |
US20210228549A1 (en) * | 2015-03-03 | 2021-07-29 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
PL3265448T3 (pl) * | 2015-03-03 | 2022-04-25 | Biohaven Therapeutics Ltd. | Proleki riluzolu i ich zastosowanie |
SG11201803645PA (en) | 2015-11-19 | 2018-06-28 | Biohaven Pharm Holding Co Ltd | Amine prodrugs of pharmaceutical compounds |
DK3458053T3 (da) * | 2016-05-20 | 2022-02-21 | Biohaven Therapeutics Ltd | Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling |
WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
US20210023061A1 (en) | 2017-11-12 | 2021-01-28 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole prodrugs to treat ataxias |
-
2016
- 2016-02-26 PL PL16759303T patent/PL3265448T3/pl unknown
- 2016-02-26 KR KR1020237034132A patent/KR20230147746A/ko active Application Filing
- 2016-02-26 CN CN201680025374.6A patent/CN107567438B/zh active Active
- 2016-02-26 PT PT167593037T patent/PT3265448T/pt unknown
- 2016-02-26 SI SI201631457T patent/SI3265448T1/sl unknown
- 2016-02-26 LT LTEPPCT/US2016/019787T patent/LT3265448T/lt unknown
- 2016-02-26 MX MX2017011196A patent/MX2017011196A/es unknown
- 2016-02-26 SG SG11201706831RA patent/SG11201706831RA/en unknown
- 2016-02-26 EA EA201791951A patent/EA034759B1/ru unknown
- 2016-02-26 KR KR1020177027618A patent/KR102587894B1/ko active IP Right Grant
- 2016-02-26 CA CA2978158A patent/CA2978158C/en active Active
- 2016-02-26 WO PCT/US2016/019787 patent/WO2016140879A1/en active Application Filing
- 2016-02-26 SG SG10201908354V patent/SG10201908354VA/en unknown
- 2016-02-26 AU AU2016226463A patent/AU2016226463B2/en active Active
- 2016-02-26 US US15/549,152 patent/US10639298B2/en active Active
- 2016-02-26 US US15/549,154 patent/US10485791B2/en active Active
- 2016-02-26 RS RS20220149A patent/RS62915B1/sr unknown
- 2016-02-26 DK DK16759303.7T patent/DK3265448T3/da active
- 2016-02-26 EP EP16759303.7A patent/EP3265448B1/en active Active
- 2016-02-26 WO PCT/US2016/019773 patent/WO2016140878A2/en active Application Filing
- 2016-02-26 BR BR112017018832-5A patent/BR112017018832B1/pt active IP Right Grant
- 2016-02-26 ES ES16759303T patent/ES2905318T3/es active Active
- 2016-02-26 JP JP2017546176A patent/JP6700293B2/ja active Active
- 2016-02-26 EP EP21209037.7A patent/EP4011870A1/en active Pending
- 2016-02-26 HR HRP20220208TT patent/HRP20220208T1/hr unknown
- 2016-02-26 HU HUE16759303A patent/HUE058204T2/hu unknown
-
2017
- 2017-08-14 IL IL253989A patent/IL253989B/en active IP Right Grant
- 2017-08-31 PH PH12017501576A patent/PH12017501576A1/en unknown
-
2018
- 2018-07-04 HK HK18108642.5A patent/HK1248706A1/zh unknown
-
2019
- 2019-06-24 US US16/449,948 patent/US10905681B2/en active Active
- 2019-11-20 US US16/689,150 patent/US11052070B2/en active Active
-
2020
- 2020-04-30 JP JP2020080638A patent/JP7012117B2/ja active Active
- 2020-09-15 AU AU2020233650A patent/AU2020233650B2/en active Active
- 2020-10-15 IL IL278080A patent/IL278080B/en unknown
-
2021
- 2021-02-01 US US17/164,654 patent/US20210236471A1/en active Pending
- 2021-07-05 US US17/367,484 patent/US20230017637A1/en active Pending
-
2022
- 2022-03-30 AU AU2022202163A patent/AU2022202163B2/en active Active
-
2023
- 2023-07-29 US US18/361,838 patent/US20230381150A1/en active Pending
- 2023-07-29 US US18/361,837 patent/US20230381149A1/en active Pending
- 2023-07-29 US US18/361,836 patent/US20240091205A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278080A (en) | Riluzole prodrugs and their use | |
IL264258B (en) | Diazahetero-bicyclic substituted compounds and their use | |
IL264813B (en) | 2-oxo-imidazopyridines and their use | |
HK1247576A1 (zh) | 氧雜二環庚烷前藥 | |
IL268048A (en) | Preparation salts and compounds of 1-methyl-d-tryptophan | |
GB201504763D0 (en) | Compounds and uses | |
HK1243077A1 (zh) | 呱啶基吡唑並嘧啶酮及其用途 | |
HK1256902A1 (zh) | 氯犬尿氨酸的前體藥物 | |
GB201522309D0 (en) | Use | |
GB201522311D0 (en) | Use | |
GB201521085D0 (en) | Use | |
GB201518466D0 (en) | Use | |
GB201515194D0 (en) | Nappy and insert therefor | |
GB201510077D0 (en) | Use | |
IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
GB2543375B (en) | Compounds and their uses | |
GB2545167B (en) | Cloches and use thereof | |
GB201514770D0 (en) | Compounds and their use | |
GB201522690D0 (en) | Nanostructured surfaces | |
GB201513318D0 (en) | Novel compounds and their use | |
GB201522411D0 (en) | Use | |
GB201522443D0 (en) | Use | |
GB201518142D0 (en) | Concept ABCD3 | |
AU2015132V (en) | CHACER01 Acer palmatum | |
GB201515987D0 (en) | Use |